Stay updated on VB-111 Combo in Recurrent Glioblastoma Clinical Trial

Sign up to get notified when there's something new on the VB-111 Combo in Recurrent Glioblastoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the VB-111 Combo in Recurrent Glioblastoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:43:22.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in a medical and healthcare-related publication or documentation, possibly related to a Phase 3 clinical trial comparing VB-111 plus bevacizumab to bevacizumab in patients with recurrent Glioblastoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:50:09.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying conditions such as the progression of Glioblastoma, measurable disease by RANO criteria, and age requirements. Previously, no information was provided under Participation Criteria Collaborators and Investigators.
    Difference
    23%
    Check dated 2024-05-22T21:38:34.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T23:19:41.000Z thumbnail image

Stay in the know with updates to VB-111 Combo in Recurrent Glioblastoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the VB-111 Combo in Recurrent Glioblastoma Clinical Trial page.